SuperworthRocket Pharmaceuticals EPS RCKT
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$0.17
- Latest quarter, Q2 FY26
- $1.08
- Fiscal year 2025
- −$2.01
Rocket Pharmaceuticals' earnings per share was −$0.17 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $1.08.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.01 | n/a |
| FY2024 | −$2.73 | n/a |
| FY2023 | −$2.94 | n/a |
| FY2022 | −$3.24 | n/a |
| FY2021 | −$2.68 | n/a |
| FY2020 | −$2.52 | n/a |
| FY2019 | −$1.58 | n/a |
| FY2018 | −$1.88 | n/a |
| FY2017 | −$2.85 | n/a |
| FY2016 | −$6.40 | n/a |
| FY2015 | −$12.60 | n/a |
| FY2014 | −$54.12 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $1.08 | n/a | −$0.17 | |
| Q1 FY26 | −$0.42 | n/a | −$1.87 | |
| Q4 FY25 | −$0.38 | n/a | −$2.01 | |
| Q3 FY25 | −$0.45 | n/a | −$2.25 | |
| Q2 FY25 | −$0.62 | n/a | −$2.51 | |
| Q1 FY25 | −$0.56 | n/a | −$2.63 | |
| Q4 FY24 | −$0.62 | n/a | −$2.73 | |
| Q3 FY24 | −$0.71 | n/a | −$2.75 | |
| Q2 FY24 | −$0.74 | n/a | −$2.79 | |
| Q1 FY24 | −$0.66 | n/a | −$2.87 | |
| Q4 FY23 | −$0.64 | n/a | −$2.94 | |
| Q3 FY23 | −$0.75 | n/a | −$3.17 |
Against its peers
Companies in Drug Manufacturers - General nearest Rocket Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| RCKTRocket Pharmaceuticals | −$0.17 | |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| LFVNLifevantage | $0.40 | −46% a year |
| SPROSpero Therapeutics | $0.11 | |
| Peer median | $0.78 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Rocket Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.